Welcome to our latest update on the outsourced Pharma Commercialisation Services sector. As well as our usual update on M&A activity, this report takes a deep dive into one of the biggest challenges businesses are currently facing – the War for Talent. A big thank you to those business leaders who took part in the survey and gave their views on this crucial issue.
So, what did the survey reveal?
-
The vast majority of respondents viewed the war for talent as a key challenge
-
Many leaders see this as a near-term risk to business performance with some seeing it as a major concern
-
Over the longer-term, some believe they can adapt to this environment, but the majority believe it will continue to drag on growth
-
Both recruitment and retention are an issue within this sector, but recruitment is viewed as the more challenging of the two
-
Unfortunately, the war for talent is not expected to end any time soon. However, a sizeable minority are optimistic about pressures easing next year
-
Business leaders have been resourceful in their attempts to attract and retain staff with many trying various methods to keep hold of talent. Of these, adopting flexible working has been most popular
-
These measures have had some success as mitigations, but more lasting solutions remain elusive
Despite these challenges 2022 looks set to be a strong year for commercialisation deal activity. More deals were completed in H1 2022 versus H1 2021, with Europe driving a lot of this growth. Despite the macroeconomic backdrop the pace does not appear to be slowing – 2022 has the potential to be a record year.
We hope that you enjoy this report and look forward to discussing the data and underlying themes with you.
Do get in touch!